Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9592 + volrustomig
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**AZD9592 + volrustomig** is a combination of two investigational antibodies being evaluated for treatment of advanced solid tumors. AZD9592 is an antibody-drug conjugate with a bispecific monoclonal antibody targeting **epidermal growth factor receptor (EGFR)** and **mesenchymal-epithelial transition tyrosine kinase receptor (c-MET)**, conjugated to a **topoisomerase 1 inhibitor (TOP1i) warhead**. Upon internalization, AZD9592 traps TOP1 on DNA, leading to double-strand breaks and apoptotic tumor cell death. Volrustomig (also known as MEDI5752) is a bispecific immune checkpoint inhibitor targeting **programmed cell death protein 1 (PD-1)** and **cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)**, designed to enhance anti-tumor immunity by simultaneous dual blockade of T-cell suppressive pathways. The combination aims to maximize tumor cell kill via both direct cytotoxicity and immune-mediated effects. Both agents are under development by AstraZeneca for solid tumors, including non-small cell lung cancer and other advanced malignancies[2][4][6][7].
- Brand names
- MEDI5752 (volrustomig)
- Other names
- AZD9592 + volrustomig
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on AZD9592 + volrustomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9592 + volrustomig.